Mereo BioPharma Group Stock

Mereo BioPharma Group EBIT

The EBIT of Mereo BioPharma Group (MREO) as of Aug 7, 2026 is -47.36 M USD. In the previous year, EBIT was -28.42 M USD — a change of 66.68% (lower).

EBIT

-47.36 MUSD

YoY

66.68%

Last updated:

In 2026, Mereo BioPharma Group's EBIT was -47.36 M USD, a 66.68% increase from the -28.42 M USD EBIT recorded in the previous year.

The Mereo BioPharma Group EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M USD)
Date
EBIT (M USD)
Jan 1, 2024
-47.36 base
Jan 1, 2025 (e)
-49.16 base
Jan 1, 2026 (e)
-28.30 base
Jan 1, 2027 (e)
-27.29 base
Jan 1, 2028 (e)
46.20 base
Jan 1, 2029 (e)
-44.46 base
Jan 1, 2030 (e)
1.80 base
Jan 1, 2031 (e)
0.00 base
YEAREBIT (M USD)
2031 est -
2030 est 1.80
2029 est -44.46
2028 est 46.20
2027 est -27.29
2026 est -28.30
2025 est -49.16
2024 -47.36
2023 -28.42
2022 -53.68
2021 -28.79
2020 -48.17
2019 -50.43
2018 -45.96
2017 -45.30
2016 -36.18
2015 -13.12
Access this data via the Eulerpool API

Mereo BioPharma Group Revenue

Mereo BioPharma Group Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2024
0.00 USD
-47.36 M USD
-43.25 M USD
Jan 1, 2025 (e)
530,400.00 USD
-49.16 M USD
-48.69 M USD
Jan 1, 2026 (e)
34.28 M USD
-28.30 M USD
-27.05 M USD
Jan 1, 2027 (e)
47.53 M USD
-27.29 M USD
-32.46 M USD
Jan 1, 2028 (e)
159.56 M USD
46.20 M USD
36.20 M USD
Jan 1, 2029 (e)
44.48 M USD
-44.46 M USD
-36.68 M USD
Jan 1, 2030 (e)
105.20 M USD
1.80 M USD
0.00 USD
Jan 1, 2031 (e)
173.12 M USD
0.00 USD
44.96 M USD

Mereo BioPharma Group Margins

Mereo BioPharma Group stock margins

The Mereo BioPharma Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Mereo BioPharma Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Mereo BioPharma Group.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2024
74.26 %
- %
- %
Jan 1, 2025 (e)
74.26 %
-9,268.61 %
-9,180.69 %
Jan 1, 2026 (e)
74.26 %
-82.56 %
-78.91 %
Jan 1, 2027 (e)
74.26 %
-57.41 %
-68.30 %
Jan 1, 2028 (e)
74.26 %
28.95 %
22.68 %
Jan 1, 2029 (e)
74.26 %
-99.97 %
-82.48 %
Jan 1, 2030 (e)
74.26 %
1.71 %
0.00 %
Jan 1, 2031 (e)
74.26 %
0.00 %
25.97 %

Mereo BioPharma Group Stock analysis

What does Mereo BioPharma Group do? Mereo BioPharma Group plc was founded in 2015 and is based in Reading, UK. The company is a pharmaceutical industry company that focuses on the development of treatments for rare and unmet medical needs. Mereo BioPharma is an emerging biotechnology company that discovers, develops, and markets innovative drugs. The company employs an experienced team of scientists and researchers dedicated to developing therapies that address unmet medical needs. Mereo BioPharma specializes in four areas of interest in which it is actively working on new developments: oncology, rare diseases, gynecological and endocrine disorders, and respiratory diseases. The company aims to advance innovative drug developments that focus on rare and unmet medical needs. These typically have received little attention from larger, established pharmaceutical companies. However, they represent a tremendous opportunity to identify and successfully bring to market high-quality and effective drugs. Mereo BioPharma is listed on the London Stock Exchange (AIM) and has a strong financial foundation. Mereo is preparing to launch two new products - Alvelestat and Setrusumab - for the treatment of respiratory diseases and osteogenesis imperfecta. Mereo's business model is based on a multi-stage development pipeline: from the discovery of potential drug candidates to clinical trials and marketing. The company works closely with established partners to pool the necessary resources and expertise required for the development and successful commercialization of an outstanding product. Alvelestat is a unique therapy specifically developed for patients with alpha-1 antitrypsin deficiency. The drug is used to treat lung and liver diseases often associated with this condition. It is currently in Phase II of clinical development. Setrusumab is an innovative product for the treatment of osteogenesis imperfecta, a rare bone disorder often diagnosed in early childhood. The drug is currently in Phase III of the approval process. The company's future plans include expanding its pipeline to create treatment options for patients worldwide. Mereo utilizes advanced technologies and modern methods to foster research, development, and clinical studies and ensure the success of its products in the market. Mereo BioPharma Group plc is a young, exciting company specializing in the development of drugs for the treatment of rare and unmet medical needs. The company focuses on three strategic priorities: research and development of innovative drugs, collaboration with strong partners, and marketing and distribution of its products. Mereo has a strong financial foundation and is committed to expanding its pipeline to meet new patient needs. Mereo BioPharma Group is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Mereo BioPharma Group's EBIT

Mereo BioPharma Group's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Mereo BioPharma Group's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Mereo BioPharma Group's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Mereo BioPharma Group’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Mereo BioPharma Group stock

EBIT of Mereo BioPharma Group is -47.36 M USD in 2026.

EBIT of Mereo BioPharma Group changed from -28.42 M USD to -47.36 M USD, representing a 66.68% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Mereo BioPharma Group since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Mereo BioPharma Group historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Mereo BioPharma Group

All Key Metrics — Mereo BioPharma Group